產品詳情
簡單介紹：
CRL-2876 VCaP 人前列腺癌細胞
ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞；細胞庫管理規范，提供的細胞株背景清楚，提供參考文獻和培養條件！
詳情介紹：
CRL-2876 VCaP 人前列腺癌細胞
| Designations: | VCaP | ||
| Depositors: | KJ Pienta | ||
| Biosafety Level: | 2 [(cells produce the mouse xenotropic retrovirus Bxv-1) ] | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens | ||
| Source: | Organ: prostate Tissue: vertebral metastasis Disease: cancer Cell Type: epithelial |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Isolation: | Isolation date: 1997 | ||
| Applications: | This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer. | ||
| Tumorigenic: | Yes | ||
| Antigen Expression: | cytokeratin-18; Homo sapiens, expressed p53 antigen; Homo sapiens, expressed prostate specific antigen (PSA); Homo sapiens, expressed prostatic acid phosphatase (PAP); Homo sapiens, expressed Rb protein; Homo sapiens, expressed |
||
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 11,12 D16S539: 9 D5S818: 12 D7S820: 9,12 THO1: 9.3 TPOX: 8,11 vWA: 18,19 |
||
| Age: | 59 years | ||
| Gender: | male | ||
| Ethnicity: | Caucasian | ||
| Comments: | This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer. It was passaged as xenografts in mice then cultured in vitro. It is androgen sensitive in vitro and in vivo. Recently, it has been shown that VCaP prostate cancer cells produce the mouse xenotropic retrovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
||
| Subculturing: | Protocol:
Interval: Subculture when the cell concentration reaches between 1 X 10(5) and 2 X 10(5) cells/sq. cm. Subcultivation Ratio: 1:3 to 1:4 |
||
| Preservation: | Freeze medium: 95% growth medium; 5% DMSO Storage temperature: liquid nitrogen vapor phase |
||
| Doubling Time: | about 53 hours | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002 recommended serum:ATCC 30-2020 0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101 Cell culture tested DMSO:ATCC 4-X Erythrosin B vital stain solution:ATCC 30-2404 Trypan Blue vital stain solution:ATCC 30-2402 |
||
| References: | 92253: Korenchuk S, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163-168, 2001. PubMed: 11317522 16173979: Knouf EC, et al. Multiple Integrated Copies and High-Level Production of the Human Retrovirus XMRV from 22Rv1 Prostate Carcinoma Cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664 16173980: Sfanos KS, et al. Identification of replication competent murine gamma retroviruses in commonly used prostate cancer cell lines. PLoS One 6:e20874, 2011. |
||
